TAK 648

Drug Profile

TAK 648

Alternative Names: TAK-648

Latest Information Update: 23 May 2016

Price : $50

At a glance

  • Originator Takeda
  • Class Antihyperglycaemics
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic nephropathies

Most Recent Events

  • 10 May 2016 Discontinued - Phase-I for Diabetic nephropathies (In volunteers) in USA (PO; liquid, tablet)
  • 01 Jul 2015 Takeda completes a phase I trial in Diabetic nephropathies (In volunteers) in USA (PO, Solution) (NCT02684396)
  • 01 Jul 2015 Takeda initiates a phase I trial in Diabetic nephropathies (In volunteers) in USA (PO, Solution) (NCT02480439)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top